OMass Therapeutics raises €275M Series C

OMass Therapeutics, a University of Oxford spin-out developing small-molecule drugs, raised an oversubscribed €275 million ($230 million) Series C round. New investors Bain Capital Life Sciences, Forbion and Novo Holdings co-led the round, with Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences also participating. Existing backers Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank and the University of Oxford all joined. The company said proceeds will fund its lead programme OMS1620, a potential best-in-class MC2 receptor antagonist, through Phase 2 development in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. The money will also support earlier-stage work, including initial clinical data for a potential first-in-class SLC15A4 inhibitor for lupus and other interferon-driven diseases.

AI-generated from reports · 2 days agoUpdate

Not enough continuous observation data yet; trend chart is not drawn for now.